Mieko Yanagisawa

Summary

Affiliation: Chugai Pharmaceutical Co
Country: Japan

Publications

  1. ncbi request reprint Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models
    Mieko Yanagisawa
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Kanagawa 247 8530, Japan
    Oncol Rep 22:241-7. 2009
  2. doi request reprint Bevacizumab improves the delivery and efficacy of paclitaxel
    Mieko Yanagisawa
    Department of Product Research, Chugai Pharmaceutical Co, Ltd, Kajiwara, Kamakura, Japan
    Anticancer Drugs 21:687-94. 2010
  3. doi request reprint Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes
    Hideyuki Yasuno
    Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, Kamakura 247 8530, Japan
    Oncol Rep 29:451-8. 2013
  4. pmc Biomarkers for antitumor activity of bevacizumab in gastric cancer models
    Yoriko Yamashita-Kashima
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Kamakura, Kanagawa, Japan
    BMC Cancer 12:37. 2012
  5. ncbi request reprint Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models
    Kaori F Ouchi
    Product Research Department, Chugai Pharmaceutical Company Ltd, 200 Kajiwara Kamakura, Kanagawa, 247 8530, Japan
    Cancer Chemother Pharmacol 57:693-702. 2006
  6. pmc Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
    Koh Furugaki
    Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, Kajiwara, Kamakura, Kanagawa, Japan
    Clin Exp Metastasis 28:649-59. 2011

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models
    Mieko Yanagisawa
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Kanagawa 247 8530, Japan
    Oncol Rep 22:241-7. 2009
    ..We will further investigate the mechanisms of the combination therapies using these models...
  2. doi request reprint Bevacizumab improves the delivery and efficacy of paclitaxel
    Mieko Yanagisawa
    Department of Product Research, Chugai Pharmaceutical Co, Ltd, Kajiwara, Kamakura, Japan
    Anticancer Drugs 21:687-94. 2010
    ....
  3. doi request reprint Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes
    Hideyuki Yasuno
    Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, Kamakura 247 8530, Japan
    Oncol Rep 29:451-8. 2013
    ....
  4. pmc Biomarkers for antitumor activity of bevacizumab in gastric cancer models
    Yoriko Yamashita-Kashima
    Product Research Department, Chugai Pharmaceutical Co, Ltd, Kamakura, Kanagawa, Japan
    BMC Cancer 12:37. 2012
    ..Therefore, we tried to identify the predictive markers for efficacy of bevacizumab in gastric cancer patients by using bevacizumab-sensitive and insensitive tumor models...
  5. ncbi request reprint Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models
    Kaori F Ouchi
    Product Research Department, Chugai Pharmaceutical Company Ltd, 200 Kajiwara Kamakura, Kanagawa, 247 8530, Japan
    Cancer Chemother Pharmacol 57:693-702. 2006
    ....
  6. pmc Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
    Koh Furugaki
    Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, Kajiwara, Kamakura, Kanagawa, Japan
    Clin Exp Metastasis 28:649-59. 2011
    ....